FSUE Moscow Endocrine Plant (Endopharm) announced that its portfolio has been updated with a new product from the list of vital and essential drugs used in anesthesiology and intensive care. The manufacturer will launch TN Sugammadex, a neuromuscular blockade drug (INN sugammadex) in two dosage forms: ampules and vials. The product is a generic version of the foreign drug Bridion.
The Russian Ministry of Health has issued Endopharm a registration certificate for the drug, which will be available in the form of an intravenous solution in convenient 2- and 5-ml vials, as well as 2-ml ampoules.
The company noted their plan to organize production according to GMP standards based on the new, high-tech Lefortovsky branch production site by the end of 2026. Sugammadex is administered intravenously as a single bolus over 10 seconds. The anesthesiologist determines the dosage individually according to the indications.
Sugammadex is used in anesthesiology and intensive care to reverse steroidal non-depolarizing neuromuscular blocking drugs rocuronium bromide or vecuronium bromide in adults, as well as children and adolescents aged 2 to 17 years. It is used for the reversal of nerve-blocking agents, restoring the patient’s independent breathing after surgery.
The drug was developed by Organon, which was acquired by Schering-Plough in 2007. Schering-Plough merged with MSD (Merck & Co.) in 2009. The drug was registered in the European Union in 2008, and in the United States in 2015. Organon registered the drug in Russia in 2010.
It was previously announced that Sotex, a Russian company, began selling sugammadex under the brand name Destinil.
